Investigational drug · Phase 2
siplizumab
Also called: TCD601
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Renal Transplant Failure and Rejection, Liver Transplantation, Renal Transplantation.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
29
Any phase or sponsor naming "siplizumab"
First trial start
2022
Jun 29, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "siplizumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Renal Transplant Failure and Rejection
- Liver Transplantation
- Renal Transplantation
Approved drugs for the same conditions: Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "siplizumab" as an intervention, largest first.
- A Phase II Study of MEDI-507, Administered by Injection to Adults With PsoriasisPivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT00540618 · 420 participants · Start Sep 2001
Drug: MEDI-507; MEDI-507 and 1 more · For: Plaque Psoriasis
Sites: Phoenix, Arizona; Little Rock, Arkansas; Fresno, California · 43 sites in all
- A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney TransplantPivotal-lookingRecruiting
ITB-Med LLCIndustry
NCT07508787 · 120 participants (planned) · Start Jun 29, 2026 · Primary completion Mar 28, 2028
Drug: Siplizumab; Rabbit anti-thymocyte globulin · For: Renal Transplant Failure and Rejection
Sites: Los Angeles, California; Sacramento, California; Tampa, Florida · 27 sites in all
- Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque PsoriasisPivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT00192452 · 120 participants · Start Mar 2001
Drug: MEDI-507 · For: Psoriasis
Sites: Phoenix, Arizona; Winston-Salem, North Carolina; Tacoma, Washington
MedImmune LLCAstraZeneca (AZN)
NCT00105313 · 80 participants (planned) · Start Feb 2005
Drug: MEDI-507 · For: Lymphoma; Leukemia; Cancer
Sites: Los Angeles, California; New Haven, Connecticut; Washington D.C., District of Columbia · 11 sites in all
ITB-Med LLCIndustry
NCT05669001 · 76 participants · Start Dec 28, 2023 · Primary completion Apr 10, 2026
Drug: TCD601; belatacept and 4 more · For: Renal Transplantation
Sites: Sacramento, California; San Francisco, California; Tampa, Florida · 18 sites in all
MedImmune LLCAstraZeneca (AZN)
NCT00806208 · 34 participants · Start Jan 1999 · Primary completion Jan 2000
Drug: MEDI-507; MEDI-507 and 2 more · For: Graft-Versus-Host Disease
Sites: St Louis, Missouri; Omaha, Nebraska; Dallas, Texas
ITB-Med LLCIndustry
NCT06365437 · 33 participants · Start Jun 6, 2021 · Primary completion Dec 11, 2024
Drug: TCD601; Tacrolimus (TAC) and 3 more · For: Kidney Transplantation
Sites: Innsbruck, Austria; Vienna, Austria; Barcelona, Spain · 7 sites in all
MedImmune LLCAstraZeneca (AZN)
NCT00123942 · 31 participants (planned) · Start Apr 2004
Drug: MEDI-507 · For: Lymphoproliferative Disorders
Sites: Bethesda, Maryland
- Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGHActive, not recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT04540380 · 20 participants (planned) · Start Sep 1, 2021 · Primary completion Jan 2029
Drug: Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab · For: Renal Failure
Sites: Boston, Massachusetts
Massachusetts General HospitalAcademic, hospital or other
NCT05900401 · 20 participants (planned) · Start Oct 1, 2023 · Primary completion Dec 2031
Drug: Fludarabine; Cyclophosphamide and 2 more · For: Kidney Failure; Kidney Transplant; Complications; Chimera
Sites: Boston, Massachusetts
Newest research
PubMed records naming it or its code names, newest first.
- Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro.
Cvetkovski F, Razavi R, Sellberg F, et al. · Am J Transplant 2023
- Immunotherapy in indolent Non-Hodgkin's Lymphoma.
Amhaz G, Bazarbachi A, El-Cheikh J · Leuk Res Rep 2022
- Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity.
Binder C, Sellberg F, Cvetkovski F, et al. · Front Immunol 2021
- Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro.
Binder C, Sellberg F, Cvetkovski F, et al. · Front Immunol 2020
- CD2 Immunobiology.
Binder C, Cvetkovski F, Sellberg F, et al. · Front Immunol 2020
- Pharmacokinetic and pharmacodynamic study of a clinically effective anti-CD2 monoclonal antibody.
Sellberg F, Berglund D, Binder C, et al. · Scand J Immunol 2020
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.